Close Menu

NEW YORK (GenomeWeb) – As it seeks to build out its non-invasive prenatal testing business, Natera is set to move into the cancer diagnostics space.

The San Carlos, Calif.-based firm, probably best known for its Panorama NIPT launched in early 2013 for detecting fetal aneuploidies, is in the midst of preparing that test for use in the lower-risk pregnancy population. Like other NIPTs, Panorama has largely been used for higher-risk populations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sponsored by

NTRK fusions are oncogenic drivers in a variety of tumors.